Fragile X syndrome

Treatment

Can fragile X syndrome be treated?

In October 2017, the U.S. FDA granted orphan drug designation for OV101 (Ovid Therapeutics, Inc.) for the treatment of fragile X syndrome. Read more details at https://globenewswire.com/news-release/2017/10/10/1143685/0/en/Ovid-Therapeutics-Receives-Orphan-Drug-Designation-from-the-U-S-FDA-for-OV101-for-Treatment-of-Fragile-X-Syndrome.html.

Intervention also consists of symptom-based treatment, therapy, and support. Individuals with fragile X syndrome can be evaluated and treated for anxiety, ADD/ADHD, and other psychiatric concerns. They can also receive supportive therapies such as speech therapy, occupational therapy, applied behavior analysis, and medical treatment for any medical concerns that present. Early intervention with these treatments and services may help improve development and lives of children living with fragile X syndrome. Treatment currently focuses primarily on behavioral aspects of fragile X syndrome. For more information concerning intervention at any age. please visit the National Fragile X Foundation at https://fragilex.org/treatment-intervention/.

Hagerman R, Lauterborn J, Au J, Berry-Kravis E. Fragile X Syndrome and Targeted Treatment Trials. Results and problems in cell differentiation. 2012;54:297-335. doi:10.1007/978-3-642-21649-7_17.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114775/

https://fragilex.org/treatment-intervention/

http://www.cdc.gov/ncbddd/fxs/facts.html

Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the Treatment of Fragile X Syndrome. Pediatrics. 2009;123(1):378-390.

Globenewswire. Available from https://globenewswire.com/news-release/2017/10/10/1143685/0/en/Ovid-Therapeutics-Receives-Orphan-Drug-Designation-from-the-U-S-FDA-for-OV101-for-Treatment-of-Fragile-X-Syndrome.html

This content comes from a hidden element on this page.

The inline option preserves bound JavaScript events and changes, and it puts the content back where it came from when it is closed.

Remember Me